Genenta Science (GNTA) CMO Galimi discloses ADS stock option holdings on Form 3

Rhea-AI Filing Summary

Genenta Science S.p.A. director and executive officer Francesco Galimi reported his initial holdings as a new insider. The filing shows stock options over 20,000 ADSs at an exercise price of $4.36 per ADS, expiring on June 4, 2035, vesting in equal monthly installments over one year beginning June 4, 2025. It also shows stock options over 27,110 ADSs at an exercise price of $2.57 per ADS, expiring on November 1, 2035, which vested in three equal monthly installments beginning November 1, 2025 and are now fully vested. The filing lists no directly held ordinary shares or ADSs.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Galimi Francesco

(Last) (First) (Middle)

12930 VIA ESPERIA

(Street)

DEL MAR, CALIFORNIA 92014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO & Head of Development

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	0	D
American Depositary Shares ("ADSs")(1)	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	06/04/2025(2)	06/04/2035	ADSs	20,000	$4.36	D
Stock Option (right to buy)	11/01/2025(3)	11/01/2035	ADSs	27,110	$2.57	D

Explanation of Responses:

1. Each American Depositary Share represents one ordinary share, no par value, of the Issuer.

2. The stock options vest in equal monthly installments over one year beginning June 4, 2025.

3. The stock options vested in three equal monthly installments beginning November 1, 2025, and are now fully vested.

	/s/ Francesco Galimi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for Genenta Science (GNTA) disclose about Francesco Galimi?

The Form 3 shows that Francesco Galimi, CMO & Head of Development and director, reports initial holdings consisting of stock options over ADSs. It lists two option grants with specific exercise prices, vesting schedules, and expirations, but no directly held ordinary shares or ADSs.

How many Genenta Science (GNTA) ADSs are covered by Francesco Galimi’s stock options?

The filing lists options over 20,000 ADSs with a $4.36 exercise price and options over 27,110 ADSs with a $2.57 exercise price. These represent Galimi’s reported derivative holdings tied to American Depositary Shares of Genenta Science.

What are the exercise prices and expirations of Francesco Galimi’s Genenta Science (GNTA) options?

One option grant has an exercise price of $4.36 per ADS and expires on June 4, 2035. The other has an exercise price of $2.57 per ADS and expires on November 1, 2035, reflecting long-dated derivative positions.

What vesting schedules apply to Francesco Galimi’s Genenta Science (GNTA) stock options?

One option grant vests in equal monthly installments over one year beginning June 4, 2025. The second grant vested in three equal monthly installments beginning November 1, 2025 and is now fully vested, according to the footnotes.

Does the Genenta Science (GNTA) Form 3 show Francesco Galimi owning ordinary shares or ADSs outright?

The Form 3 indicates zero ordinary shares and zero ADSs held directly following the reported positions. His reported exposure comes from stock options linked to ADSs rather than directly owned Genenta Science equity at this time.

How many derivative positions does Francesco Galimi report in Genenta Science (GNTA) on this Form 3?

The filing shows two stock option positions, both described as rights to buy ADSs at fixed exercise prices. Together they cover 20,000 and 27,110 underlying ADSs, providing a defined potential equity exposure if exercised in the future.